Please confirm your editon.
Want to change your edition?Go to your My INN page.
Top 3 ASX Cannabis Stocks of 2023
What are the top ASX cannabis stocks by year-on-year performance? Here's a look at the three biggest gainers in the space.
Cannabis companies in Australia face a tricky market, as regulations for the plant vary from state to state. While medical cannabis is federally legal, recreational use is still illegal in all states but the Australian Capital Territory.
The future for recreational use may be hazy, but the Australian cannabis market continues to grow. The ASX hosts cannabis stocks that don't focus on recreational sales, such as medical cannabis providers, medical researchers and holding companies.
Below the Investing News Network has gathered the top ASX cannabis stocks by year-on-year gains. The following information was collected on January 19, 2023, and market capitalisations were above AU$10 million at the time.
1. Cronos Australia
Year-over-year gain: 66.67 percent; market cap: AU$278.27 million; current share price: AU$0.50
Cronos Australia (ASX:CRON) is a medical cannabis company that was spun off from Cronos Group (NASDAQ:CRON,TSX:CRON). The company services medical cannabis patients with nationwide distribution of its products.
As of June 30, 2022, when its latest annual report was released, Cronos Australia encompassed 24 companies in seven locations following a merger with CDA Health in December 2021. CDA Health, now a wholly owned subsidiary of Cronos Australia, has divisions such as CDA Clinics, wholesaler BHC and CanView, an online platform for doctors.
For its 2022 financial year, Cronos Australia’s product sales and medical consultation revenue reached AU$67 million compared to AU$20 million the prior year. It became the first ASX medical cannabis company to pay a dividend last August.
On January 16, 2023, Cronos announced that three CDA Clinics physical locations would be moving fully to telehealth to save on costs, as 95 percent of appointments were already taking place via telehealth.
Year-over-year gain: 27.27 percent; market cap: AU$16.1 million; current share price: AU$0.07
Hygrovest (ASX:HGV) is an investment company with three cannabis companies in its portfolio. The company was previously known as MMJ Group Holdings and operated strictly within the cannabis space, but widened its lens in December 2021 alongside its rebranding to target other medical companies as well.
The cannabis investments in its portfolio are Southern Cannabis Holdings, an unlisted Australian company that operates business “across the cannabis value chain;” Weed Me, a vertically integrated Canadian cannabis producer; and Sequoya, a European CBD product company.
3. Neurotech International
Year-over-year gain: 24.14 percent; market cap: AU$55.23 million; current share price: AU$0.072
Neurotech International (ASX:NTI) is bringing cannabis-based medicines through clinical trials. Its leading treatment is NTI164, a cannabis-based medicine featuring a high amount of the cannabinoid CBDA, alongside other minor cannabinoids. The company has performed clinical trials for the treatment of children with autism spectrum disorder using NTI164, and 93 percent showed symptom improvement. Neurotech intends to begin Phase II/III trials next.
On January 19, 2023, the company announced it has scheduled a meeting with the US Food and Drug Administration for March to discuss Neurotech's future investigational new drug submission in order to begin a clinical trial in the US.
Don't forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Lauren Kelly, hold no direct investment interest in any company mentioned in this article.
- Australian Cannabis Outlook 2021: Medical Leads the Way ... ›
- Guide to Investing in Cannabis Stocks on the ASX - Investing News ... ›
- A Guide to Investing in CBD Stocks on the ASX - Investing News ... ›
- Cannabis Weekly Round-Up: Tilray Jumps Thanks to Fiscal Results | INN ›
- Cannabis Waste Extends, How Should Investors Act? ›
- Cannabis Weekly Round-Up: Connecticut Won’t See Adult Stores This Year ›